Please assess the completion status of the following clinical trial:

Trial Title: Etanercept for the Treatment of Lupus Nephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets at least 4 of the 11 American College of Rheumatology (ACR) 1982 Revised Criteria for the Classification of SLE~* Active lupus nephritis~* Currently has antibodies to double-stranded DNA (dsDNA)~* Currently receiving treatment consisting of at least 1.5 g/day of MMF OR at least 720 mg/day orally of Mycophenolic Acid OR at least 1.5 mg/kg once per day of AZA for lupus nephritis, for at least 28 days prior to study entry~* Stable medication regimen for at least 4 weeks prior to study entry~* Able and willing to self-administer study drug OR has a designated caregiver at home to administer study drug injections~* Willing to use acceptable forms of contraception for the duration of the study~Exclusion Criteria:~* Moderately severe anemia~* Neutropenia~* Thrombocytopenia~* Blood creatinine levels greater than 3.0 mg/dl~* Positive PPD without ongoing treatment for at least 30 days prior to study entry~* Pulmonary fibrotic changes~* Active infections (e.g., HIV, hepatitis B virus \[HBV\], hepatitis C virus \[HCV\]) and/or serologic evidence of prior exposure to hepatitis B~* Received a live vaccine within 3 months prior to study entry~* Doubled serum creatinine levels within the 3 months prior to study entry OR end-stage kidney disease~* Dialysis-dependent end-stage kidney disease or membranous nephritis~* History of cancer. Individuals with a history of cervical carcinoma in situ and resected basal and squamous cell carcinomas of the skin are not excluded.~* Receiving prednisone greater than 20 mg/day or equivalent corticosteroid treatment~* Pulse intravenous methylprednisolone within 30 days prior to study entry~* Receiving immunosuppressive agents other than prednisone, MMF, Mycophenolic Acid, AZA, or hydroxychloroquine~* Oral or intravenous cyclosporine, leflunomide IVIG, or plasmapheresis within 3 months prior to study entry~* Current or previous cyclophosphamide treatment~* Use of other experimental agent within 90 days prior to study entry~* Severe, progressive, or uncontrolled kidney, liver, blood, stomach, lung, heart, or brain disease. Individuals with any of these conditions that are related to active SLE are not excluded.~* Previous use of rituximab within 12 months prior to study entry~* Previous or current exposure to any of the following: etanercept (Enbrel), adalimumab (Humira), infliximab (Remicade), or anakinra (Kineret)~* Meets New York Heart Association classification of congestive heart failure (CHF) Class III or greater~* History of myocardial infarction or ischemia~* Current or history of substance abuse~* Known hypersensitivity to any component of the study drug~* Poorly controlled or advanced diabetes mellitus~* History of multiple sclerosis, transverse myelitis, optic neuritis, or epilepsy~* History of noncompliance with other therapies~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Etanercept (Type: EXPERIMENTAL): Participants in this group will self-administer 50 mg etanercept injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).
- Placebo (Type: PLACEBO_COMPARATOR): Participants in this group will self-administer 50 mg placebo injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).

Based on this trial design, predict the completion outcome and termination type (if applicable).